HC Wainwright Has Positive Outlook of MNPR FY2024 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Research analysts at HC Wainwright increased their FY2024 EPS estimates for shares of Monopar Therapeutics in a research note issued on Monday, November 11th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($1.68) per share for the year, up from their previous estimate of ($2.06). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($1.48) EPS.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.09.

Separately, Rodman & Renshaw initiated coverage on Monopar Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $50.00 price objective for the company.

Monopar Therapeutics Stock Performance

MNPR stock opened at $19.23 on Thursday. Monopar Therapeutics has a one year low of $1.37 and a one year high of $38.50. The company has a fifty day moving average of $8.47 and a 200-day moving average of $5.10. The stock has a market capitalization of $101.53 million, a PE ratio of -9.76 and a beta of 1.09.

Insider Activity at Monopar Therapeutics

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan purchased 1,550 shares of Monopar Therapeutics stock in a transaction dated Monday, October 28th. The shares were bought at an average cost of $16.25 per share, for a total transaction of $25,187.50. Following the transaction, the chief financial officer now owns 1,550 shares in the company, valued at $25,187.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 34.90% of the stock is currently owned by corporate insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.